Arca
Skip to content
Tools
Tools

NDA 210168: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 210168's history or Cipla USA's company page.

On Mar 22, 2024, FDA declined to approve NDA 210168 (NDA 210168) from Cipla USA, Inc. in its present form, citing facility inspections. openFDA lists it as not yet approved.

  • Letter date: Mar 22, 2024
  • Application: NDA 210168
  • Since then: Not approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspections

The Letter

Text from openFDA; FDA's scanned original (PDF) โ†—

Dear Ms. Crawley:

Please refer to your new drug a

We acknowledge receipt of your amendment dated , which constituted a complete response to our , action letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

FACILITY INSPECTIONS

During a recent surveillance inspection of the) a manufacturing facility for this application, our field investigator conveyed iciencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

ADDITIONAL COMMENTS

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under

21 CFR 314.65. You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products.

If you have any questions, please call oe

Sincerely,

{See appended electronic signature page} (b) (4)

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Signature Page 1 of 1

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

(b) (4)

03/22/2024 11:33:23 AM

Other Letters on This Application

  • NDA 210168Jun 20, 2025 ยท NDA 210168 ยท not approved

Record

Company
Cipla USA, Inc.
Application
NDA 210168
Status in openFDA
Unapproved

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.